Targeting PAR1: Now What?

Trends in Pharmacological Sciences

Volumn 38, Issue 8, 2017, Pages 701-716

  Flaumenhaft, Robert ^a   De Ceunynck, Karen ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

activated protein C; parmodulins; pepducins; protease activated receptor 1; vorapaxar

Indexed keywords

ACTIVATED PROTEIN C; BETA ARRESTIN; COLLAGENASE 3; DROTRECOGIN; G PROTEIN COUPLED RECEPTOR; GELATINASE A; GELATINASE B; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; INTERSTITIAL COLLAGENASE; PROTEINASE ACTIVATED RECEPTOR; SERINE PROTEINASE; THROMBIN; THROMBIN RECEPTOR; VORAPAXAR; LACTONE; PEPTIDE; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR 1; PYRIDINE DERIVATIVE; RECOMBINANT PROTEIN;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; BINDING SITE; CELL SURFACE; CONFORMATIONAL TRANSITION; DRUG EFFICACY; EPITHELIUM CELL; EXOCYTOSIS; HUMAN; HYDROPHOBICITY; IMMUNOCOMPETENT CELL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REVIEW; SMOOTH MUSCLE CELL; THROMBOCYTE AGGREGATION; ANIMAL; ANTAGONISTS AND INHIBITORS; MOLECULARLY TARGETED THERAPY;

ANIMALS; HUMANS; LACTONES; MOLECULAR TARGETED THERAPY; PEPTIDES; PROTEIN C; PYRIDINES; RECEPTOR, PAR-1; RECOMBINANT PROTEINS;

EID: 85019688103     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2017.05.001     Document Type: Review

References (124)

1. Vu, T.K., et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64 (1991), 1057–1068.
2. Zhang, C., et al. High-resolution crystal structure of human protease-activated receptor 1. Nature 492 (2012), 387–392.
3. Ayoub, M.A., et al. Real-time analysis of agonist-induced activation of protease-activated receptor 1/Galphai1 protein complex measured by bioluminescence resonance energy transfer in living cells. Mol. Pharmacol. 71 (2007), 1329–1340.
4. Ayoub, M.A., et al. Differential association modes of the thrombin receptor PAR1 with Galphai1, Galpha12, and beta-arrestin 1. FASEB J. 24 (2010), 3522–3535.
5. Soh, U.J., Trejo, J., Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through beta-arrestin and dishevelled-2 scaffolds. Proc. Natl. Acad. Sci. U. S. A. 108 (2012), E1372–E1380.
6. Dowal, L., Flaumenhaft, R., Targeting platelet G-protein coupled receptors (GPCRs): looking beyond conventional GPCR antagonism. Curr. Vasc. Pharmacol. 8 (2010), 140–154.
7. Canto, I., et al. Allosteric modulation of protease-activated receptor signaling. Mini Rev. Med. Chem. 12 (2012), 804–811.
8. Koukos, G., et al. Serine and metalloprotease signaling through PAR1 in arterial thrombosis and vascular injury. IUBMB Life 63 (2011), 412–418.
9. Mosnier, L.O., et al. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood 120 (2012), 5237–5246.
10. Trivedi, V., et al. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 137 (2009), 332–343.
11. Tressel, S.L., et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol. Med. 3 (2011), 370–384.
12. Sebastiano, M., et al. A novel mechanism regulating human platelet activation by MMP-2-mediated PAR1 biased signaling. Blood 129 (2017), 883–895.
13. Seeley, S., et al. Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. Chem. Biol. 10 (2003), 1033–1041.
14. Malovichko, M.V., et al. Ligand binding to anion-binding exosites regulates conformational properties of thrombin. J. Biol. Chem. 288 (2013), 8667–8678.
15. Ludeman, M.J., et al. PAR1 cleavage and signaling in response to activated protein C and thrombin. J. Biol. Chem. 280 (2005), 13122–13128.
16. Riewald, M., et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296 (2002), 1880–1882.
17. Bae, J.S., et al. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 110 (2007), 3909–3916.
18. Russo, A., et al. Caveolae are required for protease-selective signaling by protease-activated receptor-1. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 6393–6397.
19. Roy, R., et al. Occupancy of human EPCR by protein C induces beta-arrestin-2 biased PAR1 signalling by both APC and thrombin. Blood 128 (2016), 1884–1893.
20. Tiruppathi, C., et al. G protein-coupled receptor kinase-5 regulates thrombin-activated signaling in endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 7440–7445.
21. van den Biggelaar, M., et al. Quantitative phosphoproteomics unveils temporal dynamics of thrombin signaling in human endothelial cells. Blood 123 (2014), e22–e36.
22. Griffin, J.H., et al. Activated protein C: biased for translation. Blood 125 (2015), 2898–2907.
23. Quinn, L.M., et al. Engineering activated protein C to maximize therapeutic efficacy. Biochem. Soc. Trans. 43 (2015), 691–695.
24. Joyce, D.E., et al. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem. 276 (2001), 11199–11203.
25. Riewald, M., Ruf, W., Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. J. Biol. Chem. 280 (2005), 19808–19814.
26. Gieseler, F., et al. Proteinase-activated receptors (PARs) – focus on receptor-receptor-interactions and their physiological and pathophysiological impact. Cell Commun. Signal., 11, 2013, 86.
27. Nieman, M.T., Protease-activated receptors in hemostasis. Blood 128 (2016), 169–177.
28. Leger, A.J., et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 113 (2006), 1244–1254.
29. O'Brien, P.J., et al. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J. Biol. Chem. 275 (2000), 13502–13509.
30. Kaneider, N.C., et al. “Role reversal” for the receptor PAR1 in sepsis-induced vascular damage. Nat. Immunol. 8 (2007), 1303–1312.
31. McLaughlin, J.N., et al. Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 5662–5667.
32. French, S.L., et al. Approval of the first protease-activated receptor antagonist: rationale, development, significance, and considerations of a novel anti-platelet agent. Blood Rev. 29 (2015), 179–189.
33. Nakanishi-Matsui, M., et al. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 404 (2000), 609–613.
34. Sambrano, G.R., et al. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 413 (2001), 74–78.
35. Connolly, T.M., et al. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb. Haemost. 72 (1994), 627–633.
36. Arachiche, A., et al. Platelet specific promoters are insufficient to express protease activated receptor 1 (PAR1) transgene in mouse platelets. PLoS One, 9, 2014, e97724.
37. Arachiche, A., et al. Calcium mobilization and protein kinase C activation downstream of protease activated receptor 4 (PAR4) is negatively regulated by PAR3 in mouse platelets. PLoS One, 8, 2013, e55740.
38. Bernatowicz, M.S., et al. Development of potent thrombin receptor antagonist peptides. J. Med. Chem. 39 (1996), 4879–4887.
39. Andrade-Gordon, P., et al. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 12257–12262.
40. Junge, C.E., et al. The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 13019–13024.
41. Hamill, C.E., et al. Protease-activated receptor 1-dependent neuronal damage involves NMDA receptor function. Exp. Neurol. 217 (2009), 136–146.
42. Derian, C.K., et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J. Pharmacol. Exp. Ther. 304 (2003), 855–861.
43. Covic, L., et al. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 643–648.
44. Covic, L., et al. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat. Med. 8 (2002), 1161–1165.
45. O'Callaghan, K., et al. Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J. Biol. Chem. 287 (2012), 12787–12796.
46. Zhang, P., et al. Allosteric activation of a G protein-coupled receptor with cell-penetrating receptor mimetics. J. Biol. Chem. 290 (2015), 15785–15798.
47. Zhang, P., et al. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation 126 (2012), 83–91.
48. Cisowski, J., et al. Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. Am. J. Pathol. 179 (2011), 513–523.
49. Gurbel, P.A., et al. Cell-penetrating pepducin therapy targeting PAR1 in subjects with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 36 (2016), 189–197.
50. Ahn, H.S., et al. Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists. Bioorg. Med. Chem. Lett. 9 (1999), 2073–2078.
51. Kato, Y., et al. In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur. J. Pharmacol. 384 (1999), 197–202.
52. Perez, M., et al. Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo. J. Med. Chem. 52 (2009), 5826–5836.
53. Matsuoka, T., et al. Inhibitory effect of E5555, an orally active thrombin receptor antagonist, on intimal hyperplasia following balloon injury. J. Am. Coll. Cardiol., 43, 2004, 68A.
54. Tello-Montoliu, A., et al. Antiplatelet therapy: thrombin receptor antagonists. Br. J. Clin. Pharmacol. 72 (2011), 658–671.
55. Kai, Y., et al. Prevention of the hypercontractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage. Stroke 38 (2007), 3259–3265.
56. Kogushi, M., et al. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. Eur. J. Pharmacol. 657 (2011), 131–137.
57. O'Donoghue, M.L., et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation 123 (2011), 1843–1853.
58. Wiviott, S.D., et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial. Circulation 123 (2011), 1854–1863.
59. Chackalamannil, S., et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J. Med. Chem. 51 (2008), 3061–3064.
60. Kosoglou, T., et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur. J. Clin. Pharmacol. 68 (2012), 249–258.
61. Becker, R.C., et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373 (2009), 919–928.
62. Tricoci, P., et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N. Engl. J. Med. 366 (2012), 20–33.
63. Morrow, D.A., et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366 (2012), 1404–1413.
64. Dowal, L., et al. Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 2951–2956.
65. Dockendorff, C., et al. Discovery of 1,3-diaminobenzenes as selective inhibitors of platelet activation at the PAR1 receptor. ACS Med. Chem. Lett. 3 (2012), 232–237.
66. Aisiku, O., et al. Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. Blood 125 (2015), 1976–1985.
67. Bernard, G.R., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344 (2001), 699–709.
68. Ranieri, V.M., et al. Drotrecogin alfa (activated) in adults with septic shock. N. Engl. J. Med. 366 (2012), 2055–2064.
69. Griffin, J.H., et al. 2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: thrombotic stroke: neuroprotective therapy by recombinant-activated protein C. Arterioscler. Thromb. Vasc. Biol. 36 (2016), 2143–2151.
70. Andreou, A.P., et al. Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke. PLoS One, 10, 2015, e0122410.
71. Gleeson, E.M., et al. Activated protein C β-glycoform promotes enhanced noncanonical PAR1 proteolysis and superior resistance to ischemic injury. Blood 126 (2015), 915–919.
72. Lyden, P., et al. Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers. Curr. Pharm. Des. 19 (2013), 7479–7485.
73. Bonaca, M.P., et al. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation 127 (2013), 1522–1529.
74. Cavender, M.A., et al. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation 131 (2015), 1047–1053.
75. Whellan, D.J., et al. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J. Am. Coll. Cardiol. 63 (2014), 1048–1057.
76. Whitehead, I., et al. Expression cloning of oncogenes by retroviral transfer of cDNA libraries. Mol. Cell. Biol. 15 (1995), 704–710.
77. Silini, A., et al. Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. Clin. Exp. Metastasis 27 (2010), 43–53.
78. Adams, G.N., et al. Colon cancer growth and dissemination relies upon thrombin, stromal PAR-1, and fibrinogen. Cancer Res. 75 (2015), 4235–4243.
79. Queiroz, K.C.S., et al. Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. Int. J. Cancer 135 (2014), 2294–2304.
80. Boire, A., et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120 (2005), 303–313.
81. Yang, E., et al. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res. 69 (2009), 6223–6231.
82. Yang, E., et al. Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2. Oncogene 35 (2016), 1529–1540.
83. Burns, K.E., Thevenin, D., Down-regulation of PAR1 activity with a pHLIP-based allosteric antagonist induces cancer cell death. Biochem. J. 472 (2015), 287–295.
84. Hernandez, N.A., et al. PAR1 is selectively over expressed in high grade breast cancer patients: a cohort study. J. Transl. Med., 7, 2009, 47.
85. Gonda, K., et al. Predictive diagnosis of the risk of breast cancer recurrence after surgery by single-particle quantum dot imaging. Sci. Rep., 5, 2015, 14322.
86. Kallis, Y.N., et al. Proteinase activated receptor 1 mediated fibrosis in a mouse model of liver injury: a role for bone marrow derived macrophages. PLoS One, 9, 2014, e86241.
87. Sonin, D.L., et al. Protease-activated receptor 1 inhibition by SCH79797 attenuates left ventricular remodeling and profibrotic activities of cardiac fibroblasts. J. Cardiovasc. Pharmacol. Ther. 18 (2013), 460–475.
88. Scotton, C.J., et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J. Clin. Invest. 119 (2009), 2550–2563.
89. Vergnolle, N., et al. A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J. Clin. Invest. 114 (2004), 1444–1456.
90. Fritze, D., et al. Thrombin mediates vagal apoptosis and dysfunction in inflammatory bowel disease. J. Gastrointest. Surg. 18 (2014), 1495–1506.
91. Khoufache, K., et al. PAR1 contributes to influenza A virus pathogenicity in mice. J. Clin. Invest. 123 (2013), 206–214.
92. Antoniak, S., et al. PAR-1 contributes to the innate immune response during viral infection. J. Clin. Invest. 123 (2013), 1310–1322.
93. Bernard, G.R., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344 (2001), 699–709.
94. Cheng, T., et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat. Med. 9 (2003), 338–342.
95. Domotor, E., et al. Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood 101 (2003), 4797–4801.
96. Cheng, T., et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat. Med. 12 (2006), 1278–1285.
97. Wang, Y., et al. 3K3A-activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice. Nat. Med. 22 (2016), 1050–1055.
98. Wijewardena, A., et al. Activated protein C to heal pressure ulcers. Int. Wound J. 13 (2016), 986–991.
99. Kapila, S., et al. Use of dermal injection of activated protein C for treatment of large chronic wounds secondary to pyoderma gangrenosum. Clin. Exp. Dermatol. 39 (2014), 785–790.
100. Whitmont, K., et al. Treatment of chronic leg ulcers with topical activated protein C. Arch. Dermatol. 144 (2008), 1479–1483.
101. Whitmont, K., et al. Treatment of chronic diabetic lower leg ulcers with activated protein C: a randomised placebo-controlled, double-blind pilot clinical trial. Int. Wound J. 12 (2015), 422–427.
102. Zhong, Z., et al. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J. Clin. Invest. 119 (2009), 3437–3449.
103. Serebruany, V.L., et al. Vorapaxar and diplopia: possible off-target PAR-receptor mismodulation. Thromb. Haemost. 115 (2016), 905–910.
104. Serebruany, V.L., et al. Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?. Am. J. Ther. 24 (2017), e139–e143.
105. Tarhan, O.R., et al. Activated protein C and normal saline infusion might prevent deleterious effects of remote acute lung injury caused by intestinal ischemia-reperfusion: an experimental study in the rat model. J. Surg. Res. 168 (2011), e81–e86.
106. Teke, Z., et al. Activated protein C prevents deleterious effects of remote reperfusion injury caused by intestinal ischemia on wound healing in the left colonic anastomoses: an experimental study in the murine model. Am. J. Surg. 196 (2008), 774–787.
107. Geiger, H., et al. Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat. Med. 18 (2012), 1123–1129.
108. Dinarvand, P., et al. Intraperitoneal administration of activated protein C prevents postsurgical adhesion band formation. Blood 125 (2015), 1339–1348.
109. Kang, J.H., et al. An extracorporeal blood-cleansing device for sepsis therapy. Nat. Med. 20 (2014), 1211–1216.
110. David, S., et al. Mending leaky blood vessels: the angiopoietin-Tie2 pathway in sepsis. J. Pharmacol. Exp. Ther. 345 (2013), 2–6.
111. Andrade-Gordon, P., et al. Administration of a potent antagonist of protease-activated receptor-1 (PAR1) attenuates vascular restenosis following balloon angioplasty in rats. J. Pharmacol. Exp. Ther. 298 (2001), 34–42.
112. Lin, C., et al. Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis. Thorax 69 (2014), 152–160.
113. Strande, J.L., et al. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res. Cardiol. 102 (2007), 350–358.
114. El Eter, E.A., Aldrees, A., Inhibition of proinflammatory cytokines by SCH79797, a selective protease-activated receptor 1 antagonist, protects rat kidney against ischemia-reperfusion injury. Shock 37 (2012), 639–644.
115. Yan, J., et al. Role of SCH79797 in maintaining vascular integrity in rat model of subarachnoid hemorrhage. Stroke 44 (2013), 1410–1417.
116. Dumas, M., et al. Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist. Br. J. Pharmacol. 165 (2012), 1827–1835.
117. Chieng-Yane, P., et al. Protease-activated receptor-1 antagonist F 16618 reduces arterial restenosis by down-regulation of tumor necrosis factor alpha and matrix metalloproteinase 7 expression, migration, and proliferation of vascular smooth muscle cells. J. Pharmacol. Exp. Ther. 336 (2011), 643–651.
118. Kato, Y., et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur. J. Pharmacol. 473 (2003), 163–169.
119. Mosnier, L.O., et al. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood 104 (2004), 1740–1744.
120. Guo, H., et al. Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. J. Neurochem. 109 (2009), 116–124.
121. Kerschen, E.J., et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J. Exp. Med. 204 (2007), 2439–2448.
122. Gupta, A., et al. Distinct functions of activated protein C differentially attenuate acute kidney injury. J. Am. Soc. Nephrol. 20 (2009), 267–277.
123. Goto, S., et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J. Atheroscler. Thromb. 17 (2010), 156–164.
124. Kager, L.M., et al. Intrabronchial activated protein C enhances lipopolysaccharide-induced pulmonary responses. Eur. Respir. J. 42 (2013), 188–197.